We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma.
- Authors
Papi, Alberto; Corren, Jonathan; Castro, Mario; Domingo, Christian; Rogers, Linda; Chapman, Kenneth R.; Jackson, Daniel J.; Daizadeh, Nadia; Pandit‐Abid, Nami; Gall, Rebecca; Jacob‐Nara, Juby A.; Rowe, Paul J.; Deniz, Yamo; Ortiz, Benjamin
- Abstract
Background: Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV1) in patients with moderate‐to‐severe asthma and elevated type 2 biomarkers from phase 3 LIBERTY ASTHMA QUEST (NCT02414854). Methods: Changes from baseline in pre‐ and post‐bronchodilator (BD) FEV1 and 5‐item Asthma Control Questionnaire (ACQ‐5) scores were assessed in patients with elevated type 2 biomarkers at baseline (type 2–150/25: eosinophils ≥150 cells/μl and/or fractional exhaled nitric oxide [FeNO] ≥25 ppb; type 2–300/25: eosinophils ≥300 cells/μl and/or FeNO ≥25 ppb), stratified as exacerbators (≥1 severe exacerbation during the study) or non‐exacerbators. Results: In exacerbators and non‐exacerbators, dupilumab increased pre‐BD FEV1 by Week 2 vs placebo; differences were maintained to Week 52 (type 2–150/25: LS mean difference (LSMD) vs placebo: 0.17 L (95% CI: 0.10–0.24) and 0.17 L (0.12–0.23); type 2–300/25: 0.22 L (0.13–0.30) and 0.21 L (0.15–0.28)), in exacerbators and non‐exacerbators, respectively (p <.0001). Similar trends were seen for post‐BD FEV1. Dupilumab vs placebo also showed significantly greater improvements in post‐BD FEV1 0–42 days after first severe exacerbation in type 2–150/25 (LSMD vs placebo: 0.13 L [0.06–0.20]; p =.006) and type 2–300/25 (0.14 L [0.06–0.22]; p =.001) patients. ACQ‐5 improvements were greater with dupilumab vs placebo in both groups. Conclusion: Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study.
- Subjects
DUPILUMAB; DISEASE exacerbation; FORCED expiratory volume; LUNGS; ASTHMA; COUGH
- Publication
Allergy, 2023, Vol 78, Issue 1, p233
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15456